Zhimeng Biopharma Completes Enrollment in Phase 2/3 ALS Trial
Zhimeng Biopharma said it has completed patient enrollment in the pivotal Phase 2/3 trial of investigational drug CB03-154 for ALS.
Related stories
IndiGo Says Global Microsoft Service Disruption Is Fully Resolved
IndiGo said a global Microsoft service disruption affecting its email support services has been fully resolved.
M impact | EQUITY | Nov 14, 2026, 07:36 AM UTC
FAA Tech Failure Grounds Flights for Nearly Five Hours
Air travel ground to a halt for almost five hours Friday after an overloaded air traffic control system failed, snarling operations at Sea-Tac.
M impact | EQUITY | Nov 14, 2026, 07:32 AM UTC
Microsoft Restores Outlook and Teams After Global Outage
Microsoft says service to Outlook and Teams has been restored after a global outage.
M impact | EQUITY | Nov 14, 2026, 07:23 AM UTC
Procter & Gamble’s St. Louis Operation Marks 100 Years
A Q&A discusses the operation’s history, AI and Cascade dishwasher pods.
M impact | EQUITY | Nov 14, 2026, 07:17 AM UTC
Microsoft Restores Services After Global Outage
Microsoft said services had fully recovered across Teams, Outlook, Copilot and other applications, ending an outage that disrupted online communications for businesses and governme
M impact | EQUITY | Nov 14, 2026, 06:49 AM UTC
Microsoft Says All Services Restored After Global Outage
Microsoft said all services were restored after a global outage.
M impact | EQUITY | Nov 14, 2026, 06:49 AM UTC